"Sehat Terjangkau" Program

“Sehat Terjangkau bersama GSK” is GlaxoSmithKline (GSK) Indonesia’s program to extend access to medicines to the middle-income segment of the society in Indonesia. The program is a testament to GSK Indonesia’s commitment to improving the quality of life of more Indonesians by making its globally-trusted high-quality products more affordable and accessible to more people.

Access to medicines is one of the main healthcare problems in Indonesia, where most medicines are purchased out of pocket and people’s ability to pay for medicines varies significantly. Furthermore, despite the existence of generic medicines for drugs that are already off-patent, availability and affordability of generic medicines still pose a problem in Indonesia. This is exacerbated by the high cost of patent medicines, which mostly treat chronic diseases such as cancer, asthma, et cetera. This situation creates a barrier to access to medicines, particularly for middle-to-low-income segments in casual employment who are not covered by insurance.

To address this problem, GSK Indonesia has reduced the prices of more than half of its major brands by 15-80%, making these products more affordable to more Indonesians. Effective September 1, 2010, GSK’s patented and non-patented quality products for the following common diseases and treatments were made MORE affordable to MORE Indonesians:

HIV/AIDS
Asma/PPOK
Hepatitis B
Epilepsi
Gastro-intestinal diseases
BPH (benign prostatic hyperplasia)
Diabetes
Antibiotik

The company has also expanded its distribution coverage to cover more geographical areas in Indonesia, from 21 cities to 56 cities currently, to make its products more accessible to more Indonesians. To be able to do this, GSK Indonesia Pharma Business Unit has tripled its sales force in 2010.

This price reduction initiative will never compromise the quality and efficacy of GSK products and jeopardize the safety of patients. These are the same products that doctors and patients worldwide trust, which are now made more affordable to the Indonesian people.

This initiative is the first ever and the biggest to be made by a multinational pharmaceutical company operating in Indonesia, and the second initiative that GSK has made in the Asia Pacific region after the success of GSK Philippines’ “Expanded Access Program” that was implemented in March 2009. Both initiatives are part of GSK’s long-term commitment to respond to the challenges of global public health, as set out by GSK’s CEO Andrew Witty, who assumed the position in 2008. Furthermore, this program also builds on GSK’s long-established practices, such as tiered-pricing for vaccines, and preferential pricing for HIV/AIDS and malaria medicines.